A multi-strategy investment firm focused on breakthrough biomedical technology companies worldwide
learn more

Venture Strategy
Our flagship venture strategy invests in privately held breakthrough biomedical technology companies at all stages, from seed to crossover

Credit Strategy
Our credit opportunities strategy provides senior-secured financing to breakthrough biomedical technology companies

Public Equities Strategy
Our public equities strategy invests in IPOs, SPACs, PIPEs, and publicly traded securities of breakthrough biomedical technology companies

Co-Investment Strategy
Our co-investment vehicles provide Catalio Limited Partners with direct access to our best deals
Venture
learn more
Credit
learn more
Public Equities
learn more
Co-Investment
learn more

About Catalio

Catalio was founded in 2020 by George Petrocheilos and R. Jacob Vogelstein to invest in the next generation of category-defining life sciences companies around the globe.  Our mission is to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management teams and financial syndicates.  To achieve this objective, we work with an elite group of the world’s best scientists, engineers and clinicians – the Catalio Venture Partners – to identify breakthrough biotechnologies; co-invest with top-tier funds; and recruit A-list talent from our collective networks.
learn more

Our Portfolio

We focus on biomedical technology companies developing next-generation drugs, devices and diagnostics, and work closely with each portfolio company to build and grow the business from inception to exit.
learn more

OUR TEAM

The Catalio team comprises a unique combination of investment professionals and world-renowned, serial scientist-entrepreneurs.  Together, we have a proven track record in starting up and spinning out category-defining businesses in the life sciences.
learn more

CONTACT

Our team works 24/7 in support of our partners, investors, and portfolio companies, so we are always happy to hear from you.
reach out now

RECENT NEWS

Congrats to our portfolio company ⁦@CambrianBio⁩ on their $100M Series C financing! Delighted to continue partnering with ⁦@C_Angermayer⁩, ⁦@JamesPeyer⁩, ⁦@brentlsaunders⁩ & their team in their quest to slow down human aging! https://t.co/kGUxldJdqy
RT @CatalioCapital: Today we are excited to announce the merger of our Healthcor Catalio SPAC ($HCAQ) with ⁦@Hyperfine⁩, founded by ⁦@JMRot…
Female founders get far less VC funding than men. Here’s a look at the numbers in Baltimore
March 2019
See More Tweets